November 16, 2017 Recall: Cannabis for Medical Purposes On November 16, 2017, Aurora Cannabis Enterprises Inc. initiated a voluntary Type II recall for one lot of Sundance borealis blend (sativa), sold in 5 g bottles, due to an error in packaging of the product. The delta-9-tetrahydrocannabinol (THC) content identified on the label was higher and the cannabidiol (CBD) content identified on the label was lower than the concentration present in the product. For lot 17-118-2042, the products packaged contained a THC value of 16.2% instead of 8.17% THC, and a CBD value of 0.05% instead of 5.91% CBD. A Type II recall refers to a situation in which the use of, or exposure to a product may cause temporary adverse health consequences, or where the probability of serious adverse health consequences is remote.